Sol-gel Technologies Ltd. cash flow statement
In fiscal 2025, Sol-gel Technologies Ltd.'s operations generated $322,000 of cash; it spent $47,000 on capital projects, leaving free cash flow of $275,000.
Cash flow statement
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −24 | −23 | −23 | −25 | −8 | −9 | −18 | −14 | 0 |
| Depreciation and amortisation | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Stock-based pay | 4 | 5 | 3 | 1 | 1 | 2 | 2 | 1 | 0 |
| Capital spending | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −26 | −25 | −23 | −26 | −8 | −10 | −18 | −14 | 0 |
| Free cash flow after stock pay | −30 | −29 | −26 | −27 | −9 | −11 | −20 | −15 | 0 |
Compare with peers
- Zhengye Biotechnology Holding Ltd cash flow
- Jaguar Health, Inc. cash flow
- Verrica Pharmaceuticals Inc. cash flow
- Scilex Holding Co cash flow
- Sunshine Biopharma Inc. cash flow
Head to head: SLGL vs ZYBTJAGX vs SLGLSLGL vs VRCA
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies